Compare Abbott Laboratories (ABT) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares MSCI China ETF — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while iShares MSCI China ETF trades at $52.9. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals.
| ABT | MCHI | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $66.99 |
52-Week Low | $82.57 | $50.48 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MCHI trades at $52.02, up 2.18% today, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The stock faces resistance at $52. Recent news highlights China's AI and export-driven factory rebound, which could benefit broad China ETFs like MCHI, but structural headwinds and value trap risks persist according to some analysts.
The outlook remains cautious due to mixed technicals and macroeconomic uncertainties. Opportunities exist if China's tech and manufacturing recovery accelerates, but risks include U.S.-China tensions, deflationary pressures, and potential regulatory changes. Investors should weigh the ETF's exposure to China's cyclical sectors against its attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
